Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 163

1.

Dose schedule of recombinant murine thrombopoietin prior to myelosuppressive and myeloablative therapy in mice.

Stefanich EG, Carlson-Zermeno CC, McEvoy K, Reich M, Fielder PJ.

Cancer Chemother Pharmacol. 2001;47(1):70-7.

PMID:
11221965
3.

A schedule of recombinant Mpl ligand highly effective at preventing lethal myelosuppression in mice given carboplatin and radiation.

Abushullaih BA, Pestina TI, Srivastava DK, Jackson CW, Daw NC.

Exp Hematol. 2001 Dec;29(12):1425-31.

PMID:
11750101
4.

Single administration of thrombopoietin to lethally irradiated mice prevents infectious and thrombotic events leading to mortality.

Mouthon MA, Gaugler MH, Van der Meeren A, Vandamme M, Gourmelon P, Wagemaker G.

Exp Hematol. 2001 Jan;29(1):30-40.

PMID:
11164103
5.

Thrombopoietin accelerates platelet, red blood cell, and neutrophil recovery in myelosuppressed mice.

Grossmann A, Lenox J, Ren HP, Humes JM, Forstrom JW, Kaushansky K, Sprugel KH.

Exp Hematol. 1996 Aug;24(10):1238-46.

PMID:
8765500
6.

Effect of c-mpl ligands after total body irradiation (TBI) with and without allogeneic hematopoietic stem cell transplantation: low-dose TBI does not prevent sensitization.

Nash RA, Takatu A, Feng Z, Slichter S, Abrams K, Espino G, Gass MJ, Georges GE, McSweeney PA, Shulman HM, Storb R.

Biol Blood Marrow Transplant. 2002;8(7):360-7.

PMID:
12171482
7.

Thrombopoietin promotes hematopoietic recovery and survival after high-dose whole body irradiation.

Mouthon MA, Van der Meeren A, Gaugler MH, Visser TP, Squiban C, Gourmelon P, Wagemaker G.

Int J Radiat Oncol Biol Phys. 1999 Mar 1;43(4):867-75.

PMID:
10098443
8.

Thrombopoietin protects mice from mortality and myelosuppression following high-dose irradiation: importance of time scheduling.

Mouthon MA, Van der Meeren A, Vandamme M, Squiban C, Gaugler MH.

Can J Physiol Pharmacol. 2002 Jul;80(7):717-21.

PMID:
12182328
9.

In vivo biological effects of various forms of thrombopoietin in a murine model of transient pancytopenia.

Thomas GR, Thibodeaux H, Errett CJ, Mathias J, Marian M, Meng G, Vandlen RL, Eaton DL.

Stem Cells. 1996;14 Suppl 1:246-55.

11.

Recombinant human thrombopoietin clinical development.

Jones DV Jr, Ashby M, Vadhan-Raj S, Somlo G, Champlin R, Gajewski J, Hellmann S, Fyfe G.

Stem Cells. 1998;16 Suppl 2:199-206.

12.

Improvement of thrombocytopenia following bone marrow transplantation by pegylated recombinant human megakaryocyte growth and development factor in mice.

Kabaya K, Shibuya K, Torii Y, Nitta Y, Ida M, Akahori H, Kato T, Kusaka M, Miyazaki H.

Bone Marrow Transplant. 1996 Dec;18(6):1035-41. Erratum in: Bone Marrow Transplant 1997 Oct;20(7):619-20.

PMID:
8971370
13.

The effects of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) on platelet recovery in breast cancer patients undergoing autologous bone marrow transplantation.

Schuster MW, Beveridge R, Frei-Lahr D, Abboud CN, Cruickshank S, Macri M, Menchaca D, Holden J, Waller EK.

Exp Hematol. 2002 Sep;30(9):1044-50.

PMID:
12225796
14.

A single intravenous dose of murine megakaryocyte growth and development factor potently stimulates platelet production, challenging the necessity for daily administration.

Daw NC, Arnold JT, Abushullaih BA, Stenberg PE, White MM, Jayawardene D, Srivastava DK, Jackson CW.

Blood. 1998 Jan 15;91(2):466-74.

15.

Administration of recombinant human IL11 after supralethal radiation exposure promotes survival in mice: interactive effect with thrombopoietin.

Van der Meeren A, Mouthon MA, Gaugler MH, Vandamme M, Gourmelon P.

Radiat Res. 2002 Jun;157(6):642-9.

PMID:
12005542
17.

Ticlopidine inhibits the prothrombotic effects of thrombopoietin and ameliorates survival after supralethal total body irradiation.

Mouthon MA, Gaugler MH, Vandamme M, Gourmelon P, Wagemaker G, Van der Meeren A.

Thromb Haemost. 2002 Feb;87(2):323-8.

PMID:
11858494
18.
19.

Recombinant human thrombopoietin (rhTPO) after autologous bone marrow transplantation: a phase I pharmacokinetic and pharmacodynamic study.

Wolff SN, Herzig R, Lynch J, Ericson SG, Greer JP, Stein R, Goodman S, Benyunes MC, Ashby M, Jones DV Jr, Fay J.

Bone Marrow Transplant. 2001 Feb;27(3):261-8.

20.

Prior and concurrent administration of recombinant human megakaryocyte growth and development factor in patients receiving consolidation chemotherapy for de novo acute myeloid leukemia--a randomized, placebo-controlled, double-blind safety and efficacy study.

Geissler K, Yin JA, Ganser A, Sanz MA, Szer J, Raghavachar A, Hoelzer D, Martinez C, Taylor K, Kanz L, To LB, Archimbaud E.

Ann Hematol. 2003 Nov;82(11):677-83. Epub 2003 Oct 3.

PMID:
14530872
Items per page

Supplemental Content

Write to the Help Desk